Spots Global Cancer Trial Database for ds stage ii plasma cell myeloma
Every month we try and update this database with for ds stage ii plasma cell myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01936090 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| NK Cells in Cord Blood Transplantation | NCT01619761 | Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ... | - 75 Years | M.D. Anderson Cancer Center | |
| FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00066638 | DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Romidepsin Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01842308 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Autologous Bone... Autologous Hema... Carfilzomib Laboratory Biom... Melphalan | 18 Years - | Mayo Clinic | |
| Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant | NCT00839956 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... | Bortezomib Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | NCT00445692 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Clarithromycin Dexamethasone Lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01605032 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Busulfan Melphalan Bortezomib Autologous Hema... Peripheral Bloo... | 18 Years - 72 Years | Albert Einstein College of Medicine | |
| Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | NCT01330173 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Vismodegib Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01936090 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | NCT00445692 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Clarithromycin Dexamethasone Lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00066638 | DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Romidepsin Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
